Treatment Options in RAI-refractory DTC in Second Line and Beyond
Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.
CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies
Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.
BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment
An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.
Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.
Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM
A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.
Marina Frimer, MD, Talks Future Treatments in Uterine Cancer
Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.
Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens
David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.
Evolution of Combination Therapy As The Standard of Care
Robert Alter, MD, weighs in on the evolution of combination therapy as the first-line standard of care for patients with metastatic clear cell RCC.
Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers
Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.
Newer First-Line Combination Therapy Options
David Aggen, MD, PhD touches on the availability of newer first-line combination treatment options for metastatic disease.
Comparison of Older First-Line, Single-Agent Therapies
Robert Alter, MD compares older, single-agent first line therapies for patients with metastatic clear cell RCC.
Treatment Options in the Frontline Setting for Metastatic HER2+ Breast Cancer
Dr Sara Hurvitz provides an overview of HER2+ breast cancer, and Dr Ruta Rao details the frontline treatment options available for metastatic cases.
Clinical Case Presentation: A 36-Year-Old Woman with Breast Cancer and Brain Metastases
Ruta Rao, MD, presents the case of a 36-year-old woman with metastatic HER2+ breast cancer and brain metastases.
PFS With Ixazomib + Pomalidomide and Dexamethasone in RRMM: Upcoming Trial Data
Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.
Novel Combination Strategies in the Treatment of Renal Cell Carcinoma
Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.
Optimizing RCC Management: Addressing Quality-of-Life Measures and Metastasis
Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.
Brian Slomovitz, MD, Discusses Previous Trials of Pembrolizumab in Endometrial Cancer
Brian Slomovitz, MD, spoke about previously conducted trials that used regimens involving pembrolizumab and chemotherapy for patients with newly diagnosed high-risk endometrial cancer at SGO 2022.
Nicolas Girard, MD, on EFS Findings With Nivolumab and Chemotherapy in Resectable NSCLC
Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.
Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL
Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.
Gennady Bratslavsky, MD, on Adjuvant Therapy in RCC
Gennady Bratslavsky, MD, spoke about the role of adjuvant therapy in renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
